Clinical Trial Update: Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating propranolol for tardive dyskinesia was withdrawn from both Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• Propranolol (propranolol)

Snippet

Sponsor: Emory University | Conditions: Tardive Dyskinesia | Phase 2, Phase 3 | Status: WITHDRAWN